ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) was down 17.5% during trading on Monday . The stock traded as low as $0.32 and last traded at $0.33. Approximately 11,807,000 shares were traded during mid-day trading, an increase of 696% from the average daily volume of 1,483,199 shares. The stock had previously closed at $0.40.
Separately, Maxim Group reiterated a “hold” rating on shares of ImmunoCellular Therapeutics in a research report on Thursday, August 24th.
ImmunoCellular Therapeutics Company Profile
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.
Receive News & Ratings for ImmunoCellular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.